| Name | Title | Contact Details |
|---|
Unlock Your Business Creativity with AI-accelerated Content Productivity. We leverage our BPR know-how and unique bottled marketing and operation expertise to help business leaders receive deeper insights using Gen AI. Embrace the AI-assisted revolution with TFS custom deep prompts, GPTs for ChatGPT Team, and individualized consulting to improve efficiency, effectiveness, and quality. Our team combines decades of expertise with a pioneering spirit. We understand AI is a transformative technology, but we also recognize the irreplaceable value of human insight and oversight. Our offerings blend the strengths of people and machines through prompt engineering, consulting, and subscription-based access to our AI knowledge base. Depending on your specific needs, one of our experts will lead your project. Contact us at info@TheFusionSyndicate.com today to learn more. ***Privacy Statement*** We value your privacy and are committed to keeping your personal information secure. We will never sell your data to a third party and will only use it to contact you regarding our services. Rest assured that we will handle your information with the utmost care and confidentiality.
The RAMPF Group stands for engineering and chemical solutions and caters to the economic and ecological needs of industry. Our range of competences includes: 🧪 Production and recycling of materials for modeling, lightweight construction, bonding, and protection ⚙️ Technical production systems for precise, dynamic positioning and automation, as well as technologies for complex composite parts production 💡 Comprehensive range of solutions and services, particularly for innovative customer-specific requirements Please find our imprint here: https://www.rampf-group.com/de/impressum/ https://www.rampf-group.com/en/imprint/
Saber Law Group is women- and minority-owned boutique employment law and litigation firm based in San Francisco. * Saber attorneys hit the ground running with deep bench expertise and diverse backgrounds. * Saber attorneys are like legal, business, and operations strategists all in one. * Saber attorneys are driven by clients long-term success, many of whom have stayed with the team for decades. Our brand of client service is in high demand. Were expanding. How do you know youre ready to join Saber? * FOCUSED – You wont let anything stand in between yourself and your end goal. * INSPIRED – You are moved to practice law beyond a paycheck or a title. * RESILIENT – You have crossed hurdles and done anything to get to the finish line. * SOCIAL – You gather to share battle stories and wins at the finish line. * PREPARED – Youre an intricate planner, and preparation is vital for you. You dont just show up and hope for the best. When you turn up, you will be in prime condition. * BRAVE –The legal profession is one of the toughest. At Saber, you will be celebrated.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.